Filing Flows › Industrials › EyePoint (EYPT)
EyePoint (EYPT) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 5, 2026 · EyePoint (EYPT) Q2 2026 earnings results →
Q2 2026 Revenue down 90% year over year to $507K
EyePoint made $507K in Q2 2026 (-90% Y/Y). Operating margin n/m, net loss $94.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $507K in Q2 2026, down 90% year over year and down 27% from the previous quarter.
Operating costs exceeded revenue by $97.4M, an operating margin of -19207.1%. Total costs grew 45% against a revenue fall of 90%. The fastest-growing cost line was Research & development (+51%). The quarter ended with a net loss of $94.5M, wider than the previous quarter's $84.8M loss.
Operating cash flow was −$62.3M. Non-cash charges added back $690K of depreciation and amortization and $10.4M of share-based compensation. Working capital and other items added $21.0M. Capital expenditures of $1.2M exceeded it, leaving free cash flow of −$63.5M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 5, 2026 | $507K | -90% | n/m | −$94.5M | −$62.3M |
| Q1 2026 | 10-Q | May 7, 2026 | $696K | -97% | n/m | −$84.8M | −$80.5M |
| Q4 2025 | 10-K | Mar 5, 2026 | $620K | -95% | n/m | −$67.6M | −$65.0M |
| Q3 2025 | 10-Q | Nov 6, 2025 | $966K | -91% | n/m | −$59.7M | −$59.4M |
| Q2 2025 | 10-Q | Aug 7, 2025 | $5.3M | -44% | n/m | −$59.4M | −$62.6M |
| Q1 2025 | 10-Q | May 8, 2025 | $24.5M | +109% | -199.7% | −$45.2M | −$53.1M |
| Q4 2024 | 10-K | Mar 6, 2025 | $11.6M | -17% | -390.4% | −$41.4M | −$35.8M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Sells to
About EyePoint
EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, in next-generation bioerodible Durasert E™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Topline data is expected for wet AMD beginning in August 2026 and for DME in the fourth quarter of 2027.
In its own words, from its 8-K, filed Aug 5, 2026.
EyePoint against its Laboratory Analytical Instruments peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -90% against the peers' median +4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| EYPT EyePoint | Q2 2026 | $507K | -90% | n/m |
| A Agilent Technologies | Q3 FY26 | $1.9B | +8% | 23.6% |
| WAT Waters | Q3 2026 | $1.8B | +121% | 7.2% |
| AVTR Avantor | Q3 2026 | $1.7B | +5% | 8.2% |
| ILMN Illumina | Q3 2026 | $1.1B | +4% | 27.0% |
| MTD Mettler Toledo International | Q3 2026 | $1.1B | +6% | 27.4% |
| BRKR Bruker | Q3 2026 | $874M | +2% | -10.4% |
| RVTY Revvity | Q3 2026 | $729M | +4% | 10.6% |
| BIO Bio-Rad Laboratories | Q3 2026 | $656M | +0.5% | -7.6% |
Source: EyePoint 10-Q on SEC EDGAR · CIK 1314102 · Laboratory Analytical Instruments
13F: who owns EYPT and who is buying
More on EYPT
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results